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Asthmatic patients may have aspirin-exacerbated respiratory disease and experience acute 
dyspnea and nasal symptoms within 3 hours after the ingestion of aspirin. This study aimed to 
evaluate the effect and outcome of daily low-dose aspirin in the treatment of moderate to severe 
asthma in patients with concomitant aspirin hypersensitivity and chronic rhinosinusitis with nasal 
polyposis (CRSwNP). 
This clinical trial was conducted from February 2014 to February 2015 on 46 adult patients 
with moderate to severe asthma accompanied by CRSwNP. Patients with a positive aspirin 
challenge were blindly randomized in three groups receiving placebo/day (A); aspirin 100 
mg/day (B); and aspirin 325mg/day (C), respectively. Clinical findings, FEV1 and ACT scores 
were recorded and compared before, during, and after treatment for 6 months 
(IRCT2015061521970N2). 
Of 46 participants at baseline, 30 patients completed this 6-month trial study. The level of 
asthma control was significant; based on Asthma Control Test (ACT) when comparing the 
results in groups A and C and also groups B and C, but it was not significant when comparing 
ACT scores between groups A and B. FEV1 before and after treatment was significant when 
comparing groups A and B, groups A and C, and groups B and C.  
To conclude, aspirin desensitization with a daily dose of 325 mg aspirin resulted in the 
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improvement of long-term control of asthma. A daily aspirin dose of 100 mg was not associated 
with such an increase in ACT score. 
 




Asthma is a heterogeneous disease of the airways, 
with various phenotypes and characteristics according 
to the clinical manifestations, type of airway 
inflammation, lung function, and triggering factors. A 
subpopulation of asthmatic patients have aspirin-
exacerbated respiratory disease (AERD) and 
experience acute dyspnea usually accompanied by 
nasal symptoms (rhinorrhea and/or nasal congestion) 
within 30 minutes to 3 hours after ingestion of aspirin 
or other nonsteroidal anti-inflammatory drugs 
(NSAIDs). These patients have the aspirin triad, 
including chronic rhinosinusitis with nasal polyposis 
(CRSwNP), moderate to severe bronchial asthma  
and, hypersensitivity reactions to aspirin or other 
NSAIDs.
1-3
 The diagnosis of AERD is made via 
clinical suspicion and an aspirin challenge test, 
however, definitive diagnosis of AERD is only done 
via an aspirin challenge.
4,5
 
The recommended approaches for the management 
of asthma with NSAID sensitivity include guideline-
based treatment of bronchial asthma,
6,7
 medical and 
surgical interventions for concomitant CRSwNP,
8 
leukotriene-modifiers, avoidance of Cyclooxygenase-1 
(COX-1) inhibitors, and in some patients, aspirin 
desensitization followed by daily treatment of high- 
dose aspirin. Aspirin desensitization is an effective 
modality in corticosteroid-dependent asthma.
9
 Previous 
studies indicated that this procedure had resulted in a 
considerable reduction in disease activity, improvement 
in the quality of life, improvement in nasal and asthma 
symptom scores, reduction in sinusitis as well as the 
rate of hospitalizations for polyp surgery, and also 
corticosteroid requirements.
9
 The daily suggested doses 
of aspirin were not the same in different studies, with a 
range between 100 mg to 1300 mg.
10
 After aspirin 
desensitization, a maintenance dose of 650 mg twice 
daily was established for 6 months, which if tolerated 
was reduced to 325 mg twice daily.
4,11
 
Considering the adverse effects of high-dose aspirin 
mentioned in some previous studies,
12
 this study aimed 
to evaluate the effect and outcome of daily low-dose 
aspirin in the treatment of moderate to severe asthma in 
patients with concomitant aspirin hypersensitivity and 
CRSwNP.  
 
PATIENTS AND METHODS 
 
Participants 
This double-blind placebo-controlled randomized 
clinical trial was conducted from February 2014 to 
February 2015 at the Allergy Department, Hazrat 
Rasoul-E-Akram Hospital, Iran University of Medical 
Sciences, Tehran. A total of 65 patients between the 
ages of 18 to 65 with moderate to severe asthma and 
CRSwNP were enrolled in this study. Moderate to 
severe asthma was defined according to the Expert 
Panel Report 3(EPR-3)
6
 and the Global Initiative for 
Asthma (GINA) 2014 guidelines.
7
 Diagnosis of 
CRSwNP was established by physical examination and 
paranasal sinus CT scan. Patients with serious systemic 
diseases (including bleeding disorders, gastrointestinal 
diseases, rheumatologic diseases, malignancies, renal 
diseases, cardiac diseases, hepatic diseases, 
psychologic diseases, and mastocytosis), pregnancy or 
breast‐feeding, history of life-threatening anaphylactic 
reactions precipitated by NSAIDs, forced expiratory 
volume in 1 second (FEV1 less than 70% of predicted 
at the time of aspirin challenge), and patients receiving 
warfarin, beta-blockers, and angiotensin-converting 
enzyme inhibitors were excluded from the study. 
Signed informed consent was obtained from the 
patients following the Code of Ethics of the World 
Medical Association (Declaration of Helsinki). This 
research has been confirmed in the Iranian Registry of 
Clinical Trials with a registration reference of 
IRCT2015061521970N2. The protocol for the research 
project has been approved by the Ethics Committee of 
Hazrat Rasoul-E-Akram Hospital with the registration 
code of IR.IUMS.REC.1394.25458.  
 
Study Design 
A questionnaire including demographic data 
including sex, age, body mass index (BMI), history of 
co-morbidities including gastroesophageal reflux 
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disease (GERD) (empirical diagnosis of GERD is made 
based on the presence of typical esophageal 
symptoms), history of aspirin/ NSAID sensitization, 
smoking or second-hand exposure was completed by a 
physician for all participants. The level of asthma 
control was assessed using an Asthma Control  
Test (ACT). Spirometry was also performed for all 
patients. The patients with moderate to severe asthma 
were treated with a combination of inhaled 
corticosteroid (ICS) and long-acting beta-agonist 
(LABA), a short-course (maximum 5 days) of oral 
corticosteroid if needed, and Leukotriene receptor 
antagonist (LTRA), according to guidelines 6,7 for three 
months. Concurrent GERD and rhinosinusitis were also 
treated. Clinical findings and ACT scores were 
recorded monthly.  
An oral aspirin challenge was performed for all 
participants during two consecutive days. Drug 
withdrawal before the oral aspirin challenge includes 
LTRA, 1 week; short-acting antihistamines, 3 days; 
LABA, tiotropium bromide and theophylline, 48 hours 
and short-acting beta-agonists and ipratropium 
bromide, 8 hours. FEV1, vital signs, nasoocular and 
respiratory symptoms were recorded before the tests, 
and then every 30 min after aspirin administration. If 
the baseline FEV1 was at least 70% of the predicted 
value, the test was carried out with increasing doses of 
25, 50, and 100 mg of aspirin on the first day and 
162.5, 325, and 325 mg on the second day, 
administered at 1.5-hour intervals under intensive 
monitoring. If the patient had a history of a severe 
hypersensitivity reaction to aspirin or NSAIDs, the test 
was started with slightly lower doses of 10 and 15 mg 
aspirin. The challenge was interrupted if a decrease of 
at least 20% in FEV1 was observed (positive reaction) 
 
or when the maximum cumulative dose of aspirin 
(1000 mg) had been reached without a fall in FEV1 of 
20% or greater and in the absence of nasoocular 
symptoms (negative reaction). The aspirin challenge 
was also considered as positive when a decrease of 
more than 15% was observed in FEV1, in association 
with severe extra-bronchial symptoms including nasal 
stuffiness and rhinorrhoea. 
Patients with a positive aspirin challenge were 
assigned to one of the three distinct groups; using 
balanced blocked randomization (Group A received 
placebo/day, group B received aspirin 100 mg/day, 
group C received aspirin 325 mg/day. Patients were 
visited monthly and their clinical findings, possible 
adverse effects, and treatment adherence were recorded 
carefully. At the end of these 6 months, the patients 
were evaluated again using ACT and FEV1, and the 
results were compared with those obtained at the 
beginning of the study. 
 
Statistical Analysis 
Statistical analysis was performed; using relevant 
statistical tests where p<0.05 was considered 





Of the 46 participants at baseline, 30 completed this 
6-month trial study, with 8 patients in group A, 9 
patients in group B, and 13 patients in group C. Figure 
1 displays the flowchart of the study and the reasons 
why several were lost to follow-up. 
Major characteristics of the three groups of patients 
have been demonstrated in Table 1. Normality for age, 
FEV1 (pre-and-post), ACT scores, and their differences 
 
Table 1. Major characteristics of the three groups of patients 






A (N=8) B (N=9) C (N=13)                     
Sex Female 37.5% 89% 69.2% 0.05* 0.2* 0.36* 
Age (mean± SD) year 44.87±9.51 39±10.16 39.61±12.65 0.24 0.33 0.9 
FEV1 (mean±SD) L/second 64.62±9.10 71.56±7.89 70.77±9.46 0.11 0.16 0.84 
ACT (mean±SD)  13±4.78 14.56±3.32 15.77±3.04 0.44 0.12 0.39 
* Mann-Whitney U test was applied. a) comparing group A and group B, b) comparing group A and group C, c) comparing group B 
and group C, Group A: Placebo Group B: Aspirin 100 mg/d Group C: Aspirin 325 mg/d,  
ACT: asthma control test, FEV1: forced expiratory volume in 1 second 
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before and after aspirin consumption were determined 
which were indicative of well-modeled normal 
distribution (Table 2 and 3). 
There was no significant difference between the 
age, gender of patients, asthma control score (using 
ACT), and FEV1 (before and after treatment) in the 
three groups. 
As shown in Table 4, differences found in FEV1 
before and after 6 months of treatment, were significant 
when comparing groups A and B, groups A and C, and 
groups B and C. But the FEV1 increments between 
groups A and C (-11.3), and groups B and C (-7.48) with 
a p-value of 0.001 were much more significant compared 
to groups A and B (-3.82) with a p-value of 0.04.  
The changes in ACT scores before and after treatment 
were compared; using the Mann-Whitney U test (Table 
5). ACT score was meaningful when comparing the 
results in groups A and C and also groups B and C 
(p<0.001), but it was not significant in comparing ACT 
scores between groups A and B (p=0.09). 
 
Table 2. A comparison of forced expiratory volume in 1 second (FEV1) in the three studied groups 
 FEV1 (mean±SD) p Mean difference 
(95% CI of difference)  Before After 
Group A (N=8) 64.62±9.10 67.25±9.13 0.17 -2.63 (-6.08 to 0.83) 
Group B (N=9) 71.56±7.86 78±5.83 0<0.001 -6.44(-8.82  to  -4.07) 
Group C (N=13) 70.77±9.46 84.69±9.35 0<0.001 -13.92(-17.38 to  -10.46) 
Group A: Placebo, Group B: Aspirin 100 mg/d, Group C: Aspirin 325 mg/d 
 
 
Table 3. A comparison of asthma control test (ACT) scores in the three studied groups 
 ACT score (mean±SD) p Mean difference 
(95% CI of difference)  Before After 
Group A (N=8) 13±4.78 14.62±3.78 0.09 -1.62(-3.62to 0.37) 
Group B (N=9) 14.56±3.32 18.11±2.93 <0.001 -3.55(-4.65 to -2.46) 
Group C (N=13) 15.77±3.03 22.15±2.48 <0.001 -6.38(-7.56 to  -5.21) 
Group A: Placebo, Group B: Aspirin 100 mg/d, Group C: Aspirin 325 mg/d 
 
Table 4. Comparison of forced expiratory volume in 1 second (FEV1) differences between each two specific groups 




(95% CI of difference) 
a 
p  
(95% CI of difference) 
b 
p  
(95% CI of difference) 
c 
Group A and B -3.82±1.76 0.046 










(-11.86 to -3.10) 
Group A and C -11.3±2.33 
Group B and C -7.48±2.10 
a) Comparing group A and group B, b) comparing group A and group C, c) comparing group B and group C, Group A: Placebo 
Group B: Aspirin 100 mg/d, Group C: Aspirin 325 mg/d 
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Figure 1. Recruitment and participation flow through the study based on the consort diagram. A total of 128 patients with 
CRSwNP and asthma were screened for aspirin hypersensitivity and 51 were eligible. Of them, 46 agreed to participate in 
this study. The patients were randomized into three groups receiving placebo, 100 mg aspirin, and 325 mg aspirin daily, 
respectively. Of 15 patients assigned to the placebo arm, 6 were lost in follow-up, and one discontinued participation due to 
surgical intervention. Six participants in the active arm received 100 mg aspirin daily doses left the study (5 were lost in 
follow-up and one discontinued participation because of a skin rash). From 16 patients assigned to the active arm with 325 
mg aspirin daily doses, only one was lost in follow-up, but two discontinued the study because of gastrointestinal disorder. 
 
 
Table 5. Comparison of asthma control test (ACT) score differences (before and after treatment) between two specific groups 
Comparison ACT difference 
(mean± SED) 
p* 
(95% CI of difference) 
a 
p* 
(95% CI of difference) 
b 
p* 
(95% CI of difference) 
c 
Group A and B -1.93±0.94 0.09 









(-4.41 to -1.24) 
Group A and C -4.76±0.75 
Group B and C -2.83±0.76 
* Mann-Whitney U test was applied. a) comparing group A and group B, b) comparing group A and group C, c) comparing group B 




In this study, we investigated the effect of low-dose 
aspirin in moderate to severe asthmatic patients with 
aspirin hypersensitivity and CRSwNP. We performed a 
comparative analysis using the data obtained from our 
patients suffering from concomitant moderate to severe 
asthma and aspirin sensitivity with two daily doses of 
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100 mg and 325 mg after successful aspirin 
desensitization procedures, in which daily doses of 325 
mg were associated with a better improvement in 
asthma control scores compared to 100 mg daily doses. 
The classic triad of symptoms including aspirin 
sensitivity, asthma, and nasal polyposis is known as 
aspirin-exacerbated respiratory disease (AERD).13 
Rajan et al have detected AERD in 7% of adult 
asthmatic patients, and twice that in severe asthmatic 
patients.
14
 Therefore, AERD usually indicates a poor 
response to the therapeutic agents and therefore a more 
challenging asthma disease course.  
Sweet et al performed a study with a daily aspirin 
dose of 1300 mg and found a significant reduction in 
the rate of emergency visits and hospitalizations in 
their asthmatic patients
3
 Berges-Gimeno et al found 
improvements in the ACT score of their patients with 
less need for short-courses of systemic corticosteroid 
therapy, lower doses of inhaled corticosteroid therapy, 
and lower rates of hospitalizations with the same 
mentioned dose of aspirin in their patients.2 Rozsasi et 
al compared two doses of aspirin after the 
desensitization procedure in their patients and 
concluded that 300 mg of daily aspirin intake was 
efficacious in the management of their patients 
resulting in a decreased need for asthma medication 
and improved pulmonary function tests.15 
Swierczynskan-Krepa performed a double-blind study 
on two groups of patients with aspirin-sensitive asthma 
and aspirin tolerant asthma and concluded that daily 
aspirin doses of 624 mg were beneficial only in those 
patients with aspirin sensitivity resulting in better ACT 
scores with less need for inhaled corticosteroids after 6 
months of treatment.
16
 In 2015, Esmailzadeh et al 
conducted a 6-month double-blind study with twice-
daily doses of 625 mg aspirin which was associated 
with considerable improvements in ACT scores and 
pulmonary function tests in the treatment group 
compared with the group of patients who received a 
placebo.
17
 Our results with low doses of aspirin were 
similar to Rozsasi et al which was associated with 
better asthma control and improvement in pulmonary 
function tests with a daily dose of 300 mg of aspirin, 
while daily doses of 100 mg were only associated with 
improvement in pulmonary function tests without 
achieving better asthma control. The clinical efficacy 
of aspirin treatment after desensitization in patients 
with AERD and its cost-effectiveness has been 
documented previously both in observational studies 
and in double-blind placebo-controlled trials.18,19 
However, considering the most common adverse 
effects including cutaneous flushing, urticaria, 
gastrointestinal bleeding, epistaxis, and asthma 
exacerbation,19 the optimal maintenance dose after 
desensitization becomes an important issue in these 
patients. For example, gastrointestinal irritation has 
been reported in <3% of patients receiving doses of 
100 mg aspirin.19 In those studies with lower doses of 
daily aspirin, the frequency of gastrointestinal 
complications and the number of patients who dropped 
out from the study due to their intolerance to the drug, 
seemed to be significantly lower compared to those 
investigating high doses of daily aspirin (650 mg 
daily), although a statistically significant relationship 
was not demonstrated.
19
 In the present study, the 
efficacy of daily doses of 325 mg was associated with a 
better improvement in asthma control scores compared 
to 100 mg daily doses. 
However, there are some limitations to this study, 
of which the first was the low number of criteria 
investigated for a clinical response to treatment (ACT 
score and FEV1). Other limitation is the small number 
of patients who participated in the study and the large 
number of participants who left the study because of 
aspirin intolerance or their non-compliance in taking 
the drug continuously.  
To conclude, it was demonstrated that aspirin 
desensitization with a daily dose of 325 mg aspirin may 
result in improvement in long-term control of asthma 
with significant increases in ACT score and pulmonary 
function test. Although daily aspirin doses of 100mg 
could increase ACT score and FEV1, it was not 
associated with a considerable improvement in asthma 
control in the patients. Further studies with larger 
sample sizes and more clinical and paraclinical criteria 
with a longer duration of evaluation are required for a 
more accurate determination of the most appropriate 
daily doses of aspirin to improve the management of 
patients with AERD. 
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